Large hour-to-hour variability has previously been demonstrated in the cerebrospinal fluid (CSF) concentrations of Alzheimer's disease (AD) biomarkers amyloid ␤ 42 (A␤ 42 ) and A␤ 40 in healthy younger subjects. We investigated the within-subject variability over 36 hours in CSF A␤ and tau proteins, in older subjects and AD patients. Six patients with mild stage AD (59 -85 years, Mini Mental State Examination (MMSE) 16 -26) and 6 healthy older volunteers (64 -77 years) received an intrathecal catheter from which, during 36 hours, each hour 6 mL of CSF was drawn. Concentrations of A␤ 42 , A␤ 40 , total tau, and phosphorylated tau were determined and the variability was analyzed. Within-subject variability within 3-hour periods was assessed as the coefficient of variation, which was comparable for these 4 biomarkers in controls (4.2%-4.6%) and AD (3.1%-5.8%). Variability over 12 hour periods was 5.3% to 9.5%. These findings suggest that CSF biomarker variability is relatively low in healthy older controls and AD patients. Furthermore, continuous sampling of CSF proved to be a useful and robust method, which may also be used to investigate AD pathogenesis and to evaluate pharmacotherapeutic interventions.
Introduction
Cerebrospinal fluid (CSF) biomarker analysis has proven to be a useful additional tool in Alzheimer's disease (AD) diagnostics Blennow et al., 2010; Dubois et al., 2007; Le Bastard et al., 2010; Paraskevas et al., 2009 ). However, between-subject and between-laboratory variability hinders the definition of clear-cutoff values for clinical practice across different institutes (de Jong et al., 2006; Lewczuk et al., 2006; Sunderland et al., 2003; Verwey et al., 2009) . Whether within-subject variability also adds to these uncertainties remains unclear.
Although concentrations of CSF amyloid ␤ protein (A␤) and tau proteins were stable in longitudinally collected samples over a period of months (Andersson et al., 2008; Blennow et al., 2007; Kanai et al., 1998) , important variability, a 1.5-to 4-fold difference between lowest and highest values of A␤ 40 and A␤ 42 , was demonstrated in a study performing hourly CSF sampling with an intrathe-cal catheter over 12 to 36 hours (Bateman et al., 2007) . Moreover, the pattern of variability suggested a circadian rhythm. This method of continuous CSF sampling may be of major value in studying both the pathophysiology of AD-related CSF biomarkers and the acute effects of future therapies on these biomarkers, but further explorative studies are needed. Until now, these data were obtained in mostly young healthy volunteers (10 out of 15 volunteers were younger than 45 years) and, therefore, this method of continuous CSF sampling should be extended to older subjects and patients with AD, in order to determine daily variability in the relevant age groups. Moreover, the within-subject variability of other AD biomarkers, i.e., total tau (t-tau) and phosphorylated tau (p-tau), have not been studied.
We hypothesized that AD patients and healthy older control subjects display within-subject (circadian) variability of CSF biomarkers. We further hypothesized that the magnitude and pattern of variability might be influenced by AD pathology and therefore differ between patients and controls. In the present study, we realized a safe and innovative methodology to longitudinally monitor and analyze the within-subject variability of CSF A␤ 40 , A␤ 42 , t-tau, and p-tau levels up to 36 hours in AD patients and healthy older control subjects.
Methods

Subjects
AD patients were recruited at the memory clinic of Radboud University Nijmegen Medical Centre (RUNMC). They were diagnosed with "probable AD" in accordance with the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria (McKhann et al., 1984) . After careful assessment all AD patients were found competent to consent (Meulenbroek et al., 2010) . The control group consisted of healthy older individuals over 50 years of age, recruited from the population using advertisements in local newspapers. Their cognitive status was examined using the Mini Mental State Examination (MMSE) and individuals with scores below 28 were excluded. All participants gave written consent to participate in the study. They underwent a thorough clinical investigation to ensure good clinical health and absence of neurological disease other than AD. This included medical history, physical, neurological, and psychiatric examination, and screening laboratory tests of blood and electrocardiogram (ECG). Six patients with AD and 6 healthy older control subjects were included in this study. There were no differences between the groups regarding gender, age (Table 1) , or any of the routine laboratory tests (data not shown). The median Mini Mental State Examination score in the AD group was 23 (range 16 -26), compared with 30 (range 29 -30; p ϭ 0.002) in the control group.
Study protocol
Participants were admitted to a specially designed research room on the evening of Day 1 to check general health, vital signs, and draw blood for laboratory tests. Between 8:00 and 9:00 AM on Day 1 an intrathecal catheter was placed, and from 10:00 AM hourly CSF samples were collected. After 36 hours of sampling the intrathecal catheter was removed and participants were observed for Table 1  Demographics and CSF biomarker characteristics of AD patients and healthy older volunteers over 36 hours   AD patients   1  2  3  4  5  6  All   Age, y  77  67  69  71  64  75  71  Gender  M  F  M  M  F  F  3:3  Number of samples  36  36  36  29  36  36  A␤ 42  Mean  136  87  79  137  102  124  110  Range  Ͻ41-178  Ͻ41-126  Ͻ41- another 12 hours before they were discharged from the hospital. On day 7 participants returned to the hospital for a check-up visit. On day 30 participants were contacted by phone and checked for any adverse events. During the 36-hour measurement period a research nurse was always present, assisting the participants and continuously monitoring for adverse events. Motion and sleep were registered every hour and meal times were standardized. Sleeping times, though, were not standardized and before each CSF collection participants were briefly awoken to ensure safe collection. All procedures and analyses were performed according to the latest guidelines on Good Clinical Practice and Good Laboratory Practice.
Placement of intrathecal catheter
The indwelling intrathecal catheter, a Perifix Softtip Catheter G20/88 mm with Perifix epidural filter 0.2 m (Braun Melsungen AG, Melsungen, Germany), was placed under local anesthesia and aseptic conditions in an operation room by an experienced anesthesiologist (Hahn et al., 2002) . A lumbar puncture was performed, using the L3-4 interspace, with a bore 18 gauge Tuohy needle. The catheter tip was advanced 10 cm into the intrathecal space. The catheter was connected to a covered bacterial filter. A loop was made in the catheter to relieve tension, and the catheter was taped over the participant's shoulder. The catheter was removed by the study physician immediately after the last sample had been taken. Subjects were observed for 12 hours after removal to ensure proper sealing of the cannula insertion point. There were no complications at the placement and after the removal of the spinal catheter.
CSF analyses
Every hour 6 mL of CSF was collected in polypropylene tubes, resulting in 36 samples. In 1 AD patient the final 7 of the 36 samples are missing due to accidental removal of the catheter, and in 1 control subject 2 nightly samples were not collected, according to the subject's preference. All samples were immediately transported to the adjacent laboratory and centrifuged at 2000g for 5 minutes to eliminate cells and other insoluble material. All CSF samples contained clear fluid and, upon visual inspection, did not contain blood. These procedures are in line with current international guidelines (Blennow et al., 1993) . Aliquots were stored at Ϫ80°C within 30 minutes after withdrawal until biochemical analysis (Schoonenboom et al., 2005) .
CSF A␤ 42 , t-tau, and p-tau were determined using the xMAP-based Innobia assay (Innogenetics NV, Ghent, Belgium) and CSF A␤ 40 was determined using enzyme-linked immunosorbent assay (ELISA) (The Genetics Company, Schlieren, Switzerland) according to the manufacturer's specifications. For validation of the results, CSF A␤ 42 , t-tau, and p-tau analyses were repeated at Merck Research laboratories (Kenilworth, NJ, USA) using the xMAP-based Innobia assay (Innogenetics NV), and CSF A␤ 42 and A␤ 40 were also repeated using an MSD multiplex assay (Mesoscale Diagnostics, Gaithersburg, MD, USA) (Supplementary Table 1 ). Total protein levels in CSF were analyzed using the Lowry method. All samples were analyzed in duplicate (except for total protein) and, to minimize interassay variation, all samples from a single participant were measured in the same plate and all samples were analyzed using identical production batch numbers. The analytical coefficients of variation (CV) for CSF analyses in this study, which were assessed by including the same sample in different analytical runs, were 11.8% for A␤ 40 , 10.2% for A␤ 42 , 9.3% for t-tau, and 8.3% for p-tau.
Statistical analyses
Descriptive statistics of all biomarkers concentrations over 36 hours were determined, both for individuals and by group. A lag phase was identified in the first hourly measurements (see Results) and to correct for this the first 3 samples in all subjects were excluded from further statistical Slats et al. / Neurobiology of Aging 33 (2012) 831.e1-831.e9 analyses. CVs for all biomarkers over 33 hours were calculated in both groups. To investigate within-subject hour-tohour fluctuations for shorter time periods, the CVs for biomarker measurements were also calculated for time periods of 3 and 12 hours using a mixed linear model with subject, time period (3-and 12-hour) and their interaction as fixed factors. The dependent variable was the logarithm of the concentrations. This resulted in an estimate of the pooled standard deviation of the logarithms of the concentrations measured within 3-or 12-hour periods, and after backtransformation in an estimate of the CV. Of note, on the logarithmic scale, 95% of the measurements differed by less than 4 standard deviations from each other. Therefore, we can state that 95% of the concentrations that were measured within a period of 3 or 12 hours varied less than approximately 4 times the CV. In this sense, this CV represents an indication for the precision of the measurements.
Time trends in the biomarker levels were analyzed by means of a linear mixed model with subject as random factor. To account for the longitudinal relationship of samples a first-order autoregressive covariance structure was used. In order to remove heteroscedasticity, all biomarker values were first log transformed. The results of the analyses were back-transformed and are presented as percentages. To investigate the presence of circadian patterns we included a cosinar analysis in the model (first order Fourier analysis). All analyses were performed using SPSS 16.0 (IBM, Armonk, NY, USA) and graphs were constructed using Sigmaplot 10.0 (Systat Software Inc, San Jose, CA, USA).
Results
Individual and group means of CSF A␤ 40 , A␤ 42 , t-tau, and p-tau for AD and controls are shown in Table 1 . A␤ 40 and A␤ 42 concentrations were lower in AD than in control, although this did not reach statistical significance, while mean t-tau (p ϭ 0.03) and p-tau (p ϭ 0.02) were significantly higher. Two healthy control subjects had low A␤ 42 levels, which, in 1 of these subjects, was also accompanied by a high t-tau and a slightly elevated p-tau.
In all subjects, in the first hours of sampling a lag phase was detected in A␤ 40 and A␤ 42 , but not in t-tau and p-tau concentrations, with values far below the 36-hour average. An example of this lag phase is depicted in a typical curve of 1 AD patient in Fig. 1A and B; CSF biomarker curves of all subjects are provided in Supplementary Fig. 1 . We performed an in vitro experiment to determine the cause of this lag phase. Through 2 catheters, 1 with and 1 without a bacterial filter attached, 8 CSF samples of 6 mL were drawn. The results demonstrated that the presence of the bacterial filter was responsible for an artificial reduction in A␤ 42 concentration of nearly 100% in the initial samples ( Fig. 2A) . Therefore, to investigate whether the bacterial filter could affect the assessment of variability, in a second experiment we tested how this filter influenced the detection of high and low CSF biomarker concentrations (Fig. 2B-D) . Eight 6-mL aliquots were drawn alternately from 2 CSF pools, 1 with high and 1 with low concentrations of A␤ 42 , t-tau, and p-tau. Results demonstrated that the bacterial filter did not substantially attenuate the differences between these high and low concentrations. More precisely, t-tau and p-tau concentrations were not altered, and high A␤ 42 concentrations were underestimated by 6% while low A␤ 42 concentrations were overestimated by 4%. Variability between the high and low concentration A␤ 42 pools (Ϯ 200%) was underestimated by 16% due to the filter.
Hour-to-hour variability of absolute CSF A␤ 40 , A␤ 42 , t-tau, and p-tau concentrations over 36 hours is shown in Fig. 3 . This graph illustrates significant within-subject variability, but also large between-subject as well as between-group variability. Variability can be expressed by the CV over 33 (36 minus lag phase) hours (Table 2) . CVs in the AD group were 10.9% for A␤ 40 , 11.1% for A␤ 42 , 18.7% for t-tau, and 13.4% for p-tau. In the control group CVs were 11.2% for A␤ 40 , 14.4% for A␤ 42 , 11.4% for t-tau, and 11.5% for p-tau. This analysis, however, is confounded by between-subject variability, as well as by the strong temporal relationship of repeated measurements.
To account for this, we first analyzed time trends in these data by means of a linear mixed model. In AD patients, but not in controls, a significant linear trend in t-tau was observed with an increase of 1.1% per hour (p Ͻ 0.001). The same linear trend was observed in p-tau in AD, with an increase of 1.0% per hour (p Ͻ 0.001).
We then explored circadian patterns in these biomarkers using a cosinar fit, which revealed a significant circadian fluctuation pattern in A␤ 40 , with an amplitude of 517 pg/mL for the AD group and 358 pg/mL for the control group (p Ͻ 0.001); in A␤ 42 , with an amplitude of 7.5 pg/mL for the AD group and 15.5 pg/mL for the control group (p Ͻ 0.005); and in p-tau, with an amplitude of 2.5 pg/mL for the AD group and 1.4 for the control group (p Ͻ 0.01). No circadian pattern was seen for t-tau in either group.
Next, we calculated the CVs for the repeated biomarker measurements within 3-and 12-hour periods throughout the 33 hours using mixed linear model analysis. For measurements within 3 hours, these CVs were in AD 3.4% for A␤ 40 , 3.1% for A␤ 42 , 4.7% for t-tau, and 5.8% for p-tau. In controls, these CVs were 4.6% for A␤ 40 , 4.6% for A␤ 42 , 4.2% for t-tau, and 4.5% for p-tau, which was not significantly different from the AD group. For measurements within 12-hour periods these CVs were in AD 5.5% for A␤ 40 , 5.7% for A␤ 42 , 9.5% for t-tau, and 7.7% for p-tau. In controls, these CVs were 5.4% for A␤ 40 , 6.7% for A␤ 42 , 5.4% for t-tau, and 5.3% for p-tau. To aid the interpretation of these 3-and 12-hour CV's, as discussed in the statistical methods section, these results imply that any 2 measurements taken within a 3-or 12-hour period will not differ by more than 20%. A reference sample was drawn directly from the CSF pool (dotted line). All samples were analyzed for A␤ 42 in duplicate with an xMAP-based Innobia assay (Innogenetics NV, Ghent, Belgium). (B, C and D) Eight 6-mL aliquots were drawn through a catheter with a bacterial filter, alternately from 2 CSF pools, 1 with high and 1 with low concentrations of A␤ 42 , t-tau, and p-tau. The high concentration of A␤ 42 in the CSF pool was created by addition of synthetic A␤ 42 to the pool, whereas the other CSF pool was used without additives. Reference samples were directly drawn from both CSF pools (dotted lines). All samples were analyzed in duplicate with an xMAP-based Innobia assay. Horizontal axes present sample numbers, uneven sample numbers are from the high concentration CSF pool, even numbers from the low concentration pool. Abbreviations: A␤, amyloid ␤ protein; p-tau, hyperphosphorylated tau; t-tau, total tau. 831.e5 D. Slats et al. / Neurobiology of Aging 33 (2012) 831.e1-831.e9 
Discussion
The method of hourly CSF sampling successfully measured variability of AD biomarkers in both healthy older controls and AD patients, extending previously published results of this method in young volunteers (Bateman et al., 2007) . The main findings are that, overall, A␤ variability was smaller than in these younger subjects, with low CV's for samples taken 3 and 12 hours apart, and significant circadian patterns. For the first time, variability in tau proteins is reported, demonstrating an as yet unexplained linear increase (baseline drift) over 36 hours.
Within-subject CVs of samples taken 1-3 or 1-12 hours apart was between 3.1% and 9.5% for CSF A␤ 40 , A␤ 42 , t-tau, and p-tau in AD patients and healthy older control subjects, with no significant difference in variability between both groups. This variability was lower than expected For validation A␤ 42 , t-tau, and p-tau were analyzed in duplo, with a Luminex, xMAP-based Innobia assay (Innogenetics NV, Ghent, Belgium) at the laboratory in RUMCN in the Netherlands and at Merck Research Laboratories (NJ, USA). A␤ 40 was analyzed using ELISA (The Genetics Company, Schlieren, Switzerland) and both A␤ 42 and A␤ 40 were also analyzed using an MSD multiplex assay (Mesoscale Diagnostics, MD, USA). The first 3 hours were excluded. The within-subject variability for each group was calculated as the coefficient of variation, separately for each analysis. All data are expressed as mean, with range (minimum-maximum), in pg/mL. Key: A␤, amyloid ␤ protein; AD, Alzheimer's disease; CSF, cerebrospinal fluid; CV, coefficient of variation; p-tau, hyperphosphorylated tau; RUNMC, Radboud University Nijmegen Medical Centre; t-tau, total tau.
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from previous work in younger subjects, which reported large hour-to-hour fluctuations in CSF biomarkers, based on visual assessment and calculation of the ratio between the maximum and minimum values over 9, 12, or 36 hours (Bateman et al., 2007) . These ratios (2.5 for A␤ 1-x , 3.1 for A␤ 40 , and 3.3 for A␤ 42 ) were higher than ratios we calculated for comparison over 36 hours from our own data; in the AD group 1.7 for A␤ 40 , 1.7 for A␤ 42 , 2.4 for t-tau, and 1.7 for p-tau, and in the control group 1.7 for A␤ 40 , 1.4 for A␤ 42 , 1.6 for t-tau, and 1.6 for p-tau. We will discuss 4 possible explanations for this difference in variability between the studies. First, the difference may be partly explained by the lag phase that was observed for A␤, but not for tau, in all subjects. We contemplated that this is an artifact due to the bacterial filter, which was confirmed using an in vitro experiment in our laboratory. That experiment demonstrated a lag phase in A␤ 42 concentration when CSF was drawn through a catheter with filter, and the absence of such a lag phase when the filter was left out. A␤ peptides are known to stick to the walls of test tubes made of glass or polystyrene, and therefore polypropylene test tubes are recommended (Vanderstichele et al., 1998) . A␤ peptides probably also stick to the filter material, which induces a lag phase, until the filter is saturated and measurements become representative. The lag phase resulted in inaccurately low A␤ values in the first few samples, which would have overestimated the 36-hour variability. Therefore these first samples were excluded from our analysis. A similar lag phase can be identified in the study with younger subjects (Bateman et al., 2007) and thus may have augmented variability, however that study did not use the bacterial filter (Bateman, personal communication) .
Second, adding to the first in vitro experiment which showed that CSF concentrations were stable after the lag phase, our second in vitro experiment investigated how alternate sampling of CSF samples with high and low biomarker concentrations would be affected by the "sticky" bacterial filter. This experiment showed that the filter had a small effect on A␤ 42 , but not t-tau or p-tau. Likely, saturation of the bacterial filter with A␤ 42 is a dynamic process during which new A␤ peptides bind to the material when CSF with a high concentration is drawn and are released when CSF with a lower concentration is drawn. This "flattening effect" on A␤ concentrations however only resulted in modest underestimation of the in vitro variability from 200% to 184%. Nonetheless, future studies using this design of continuous CSF sampling should avoid using a filter, to ensure representative variability.
Third, we used mixed modeling as a statistical method to assess CVs for the CSF biomarkers. With this method we are able to correct for between-subject variability, which is high for all biomarkers investigated here, but also to correct for temporal trends that we identified in our study, which can be artificially induced by the methodology of continuous sampling. However, also the unprocessed CVs and the ratios between maximum and minimum values yield lower variability in our dataset than in the previously described study (Bateman et al., 2007) .
The fourth and most salient explanation for the difference in variability between these studies is that the present work investigated older subjects and older AD patients, suggesting that CSF biomarker variability is reduced with aging and AD. Indeed, in the study with younger subjects a circadian pattern was observed, based on peaks and troughs that were recognized in the averaged 36-hour recordings of CSF A␤ (Bateman et al., 2007) . Using cosinar analysis, we were also able to detect a statistically significant circadian pattern in CSF A␤42 and A␤40. However, the amplitudes of these changes were much smaller, with the peak-trough difference ranging from 3.8% to 7.7%. Our study was not designed to account for circadian influences such as sleep; moreover the study environment, including nightly sampling, will have affected normal circadian physiology, therefore, further study is needed to explore the nature and cause of circadian variability in A␤. As the mechanisms behind CSF A␤ variability remain unknown, we can only speculate why variability is reduced in aging and AD. Fluctuations in the rate of neuronal production or clearance of A␤ may underlie short-term and circadian variability. However, thus far, studies that have addressed A␤ production and clearance rates, estimated by administering stable isotope-labeled amino acids, found no evidence for hour-to-hour variability. In 1 study early steady state levels of A␤ were observed over a period of 15 hours (Bateman et al., 2006) , while in another study hour-tohour changes in production of A␤ before and during administration of a ␥-secretase-inhibitor showed no circadian pattern in A␤ production (Bateman et al., 2009) . A␤ production and clearance rates, and possible changes herein, should be further characterized, as well as the influence of circadian rhythms on these factors. At the same time other possible causes for hourly variability of CSF biomarkers should be identified.
A linear increase in t-tau and p-tau concentrations over 36 hours was seen in the AD group, but not in the control group. Such a linear trend suggested a methodological artifact, likely to be caused by the catheter in vivo. This is the first study in which hourly t-tau and p-tau concentrations were described. However, previous studies have shown that these biomarkers remain stable over longer periods of time, when CSF is sampled longitudinally via lumbar punctures (Andreasen et al., 1999; Blennow et al., 2007; Zetterberg et al., 2007) . Therefore, we hypothesize that the increase seen here is a result of the substantial drainage of CSF in this study; a hypothesis that is supported by a concomitant rise in CSF total protein observed in AD but not in control subjects ( Supplementary  Fig. 2) . Apparently, healthy volunteers can compensate 831.e7 for the withdrawal of a large volume of CSF, while AD patients cannot. CSF production can be decreased in AD patients (Silverberg et al., 2001) . The cause of this decrease may be found in pathological changes of the choroid plexus, such as epithelial atrophy, basement membrane thickening, and amyloid deposition in choroidal blood vessels (Serot et al., 2000; Silverberg et al., 2003) . The steady and gradual increase of CSF total protein, and the fact that this was only observed in AD patients, argues against neuronal damage provoked by insertion of the intrathecal catheter. We speculate that the reduction in CSF volume, induced by repeated sampling, may have led to a larger than normal transfer of tau proteins from interstitial fluid (possibly containing higher concentrations of t-tau and p-tau) to CSF, resulting in a progressive rise in CSF t-tau and p-tau. Why A␤ concentrations are not affected in the same way as t-tau and p-tau by the reduction in CSF volume remains unclear. Perhaps this is due to the fact that this protein is actively cleared and that its clearance across the blood-brain barrier is still efficient. However, in a previous study it was shown that A␤ concentrations increased up to 200% of baseline over 36 hours (Bateman et al., 2009) . This difference remains unexplained. Whatever may be the cause, it is important to realize that repeated CSF sampling, especially if a large total volume is withdrawn in a short period of time, apparently alters normal physiology and may thus confound results. This is of relevance for the design and interpretation of future studies that use repeated CSF sampling.
In conclusion, short-term biological within-subject variability of CSF A␤ and tau concentrations was lower than expected, including a much less pronounced circadian pattern compared with earlier observations in younger subjects. For a practical implication, these results indicate that the time of day for a single diagnostic lumbar puncture in clinical practice does not have to be standardized. However, our results require independent confirmation in more subjects and in experiments with the use of catheters without bacterial filters. Furthermore, unraveling the mechanisms behind both the rapid fluctuations in biomarkers and their reduced variability in aging and AD, may yield important advances in our understanding of the pathogenesis of sporadic AD. Moreover, the observed differences in circadian rhythm of A␤ may hold information about its physiology and perhaps better understanding of the factors that influence A␤ concentrations may pave new ways toward treatment. Finally, these results demonstrate that, after finetuning of the method, this technique of repeated CSF sampling with a spinal catheter proves a very promising tool, not only for the study of Alzheimer pathophysiology, but also for monitoring of drug treatments in intervention studies.
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